What this means
Researchers plan to test whether an NAD+ injection can ease stiff arteries in older adults. The trial has not started, so no results exist yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40–70
- Where
- 1 site
The science
- Registered title
- Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.
- Trial ID
- NCT07328100 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Vascular Aging, NAD
- What is tested
- Coenzyme I for Injection, NaCl (placebo)
- Sponsor
- Shanghai 10th People's Hospital
- Ages
- 40 Years to 70 Years
- Dates
- First posted Jan 8, 2026 · updated Jan 8, 2026
Registry summary
Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.
Sites (1)
- Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality, China